Contact
searchSearch
HMP Global
Login

News

News
Real-World Analysis of Neoadjuvant Immune Checkpoint Inhibition for Patients With dMMR/MSI Nonmetastatic Colon Cancer
09/10/2025
Stephanie Holland
According to results from a retrospective, observational study, neoadjuvant immune checkpoint inhibitors were effective and safe among patients with mismatch repair-deficient microsatellite instability nonmetastatic colon cancer.
According to results from a retrospective, observational study, neoadjuvant immune checkpoint inhibitors were effective and safe among patients with mismatch repair-deficient microsatellite instability nonmetastatic colon cancer.
According to results from a...
09/10/2025
Oncology
News
Adding Sintilimab to Neoadjuvant Short-Course Radiotherapy Plus Chemotherapy for Newly Diagnosed Patients With Locally Advanced Rectal Cancer
08/26/2025
Stephanie Holland
According to results from the phase 2 SPRING-01 trial, adding sintilimab to neoadjuvant short-course radiotherapy plus chemotherapy significantly improved pathological complete response among newly diagnosed patients with locally advanced...
According to results from the phase 2 SPRING-01 trial, adding sintilimab to neoadjuvant short-course radiotherapy plus chemotherapy significantly improved pathological complete response among newly diagnosed patients with locally advanced...
According to results from the...
08/26/2025
Oncology
News
Efficacy, Safety of Various Total Neoadjuvant Therapy Approaches Among Patients With Locally Advanced Rectal Cancer
08/12/2025
Stephanie Holland
According to results from a case series study, various total neoadjuvant therapy approaches demonstrated similar efficacy and safety outcomes among patients with locally advanced rectal cancer.
According to results from a case series study, various total neoadjuvant therapy approaches demonstrated similar efficacy and safety outcomes among patients with locally advanced rectal cancer.
According to results from a case...
08/12/2025
Oncology
News
Avelumab Following Long-Course Chemoradiotherapy Demonstrates Clinical Promise Among Patients With Locally Advanced, Resectable Rectal Cancer
08/05/2025
Stephanie Holland
According to results from the phase 2 Ave-Rec trial, avelumab following long-course chemoradiotherapy demonstrated clinical promise among patients with locally advanced, resectable rectal cancer.
According to results from the phase 2 Ave-Rec trial, avelumab following long-course chemoradiotherapy demonstrated clinical promise among patients with locally advanced, resectable rectal cancer.
According to results from the...
08/05/2025
Oncology
Arvind Dasari, MD
Conference Coverage
Use of ctDNA Monitoring During Colorectal Cancer Treatment to Identify Patients Eligible for Curative-Intent Metastasis-Directed Therapy
08/05/2025
Arvind Dasari, MD
Arvind Dasari, MD, discusses study results which assessed the clinical utility of adding ctDNA monitoring to standard colorectal cancer treatment to better identify patients eligible for curative-intent metastasis-directed therapy.
Arvind Dasari, MD, discusses study results which assessed the clinical utility of adding ctDNA monitoring to standard colorectal cancer treatment to better identify patients eligible for curative-intent metastasis-directed therapy.
Arvind Dasari, MD, discusses...
08/05/2025
Oncology
Dirk Arnold, MD, PhD
Conference Coverage
Amivantamab Rechallenge for Patients With Left-Sided Metastatic Colorectal Cancer
07/24/2025
Dirk Arnold, MD, PhD
Dirk Arnold, MD, PhD, discusses updated results from the OrigAMI-1 trial, which assessed amivantamab rechallenge in patients with left-sided RAS/BRAF wild-type metastatic colorectal cancer who experienced disease progression after treatment...
Dirk Arnold, MD, PhD, discusses updated results from the OrigAMI-1 trial, which assessed amivantamab rechallenge in patients with left-sided RAS/BRAF wild-type metastatic colorectal cancer who experienced disease progression after treatment...
Dirk Arnold, MD, PhD, discusses...
07/24/2025
Oncology
Conference Coverage
Circulating Tumor DNA Methylation-Guided Postoperative Surveillance For Patients With Non-Metastatic Colorectal Cancer
07/08/2025
Allison Casey
According to an interim analysis of the FIND trial, ctDNA methylation-guided postoperative surveillance increased the likelihood of curative-intent treatment among patient with recurrent non-metastatic colorectal cancer.
According to an interim analysis of the FIND trial, ctDNA methylation-guided postoperative surveillance increased the likelihood of curative-intent treatment among patient with recurrent non-metastatic colorectal cancer.
According to an interim analysis...
07/08/2025
Oncology
News
Lean Body Mass-Based Dose Adjustments Significantly Reduces the Rate of Oxaliplatin-Induced Peripheral Neurotoxicity in Colon Cancer
07/01/2025
Stephanie Holland
Results from the phase 2 LEANOX trial demonstrated that using lean body mass to adjust oxaliplatin dosage significantly reduces the rate of oxaliplatin-induced peripheral neurotoxicity among patients with stage 3 colon cancer.
Results from the phase 2 LEANOX trial demonstrated that using lean body mass to adjust oxaliplatin dosage significantly reduces the rate of oxaliplatin-induced peripheral neurotoxicity among patients with stage 3 colon cancer.
Results from the phase 2 LEANOX...
07/01/2025
Oncology
Sheraz Yaqub, MD, PhD, Oslo University Hospital
Videos
Aspirin Did Not Improve Survival Outcomes for Patients With Metastatic Colorectal Cancer
06/13/2025
Sheraz Yaqub, MD, PhD
Sheraz Yaqub, MD, shares insights from a phase 3 trial evaluating aspirin as secondary prevention of colorectal cancer liver metastases.
Sheraz Yaqub, MD, shares insights from a phase 3 trial evaluating aspirin as secondary prevention of colorectal cancer liver metastases.
Sheraz Yaqub, MD, shares...
06/13/2025
Oncology
Conference Coverage
Liquid Biopsy-Guided Anti-EGFR Retreatment Improves Survival and Response Rates in Metastatic Colorectal Cancer
06/01/2025
Emily Estrada
The phase 2 PARERE trial demonstrated an overall response rate and progression-free survival advantage with liquid biopsy-guided anti-EGFR retreatment vs regorafenib for chemorefractory metastatic colorectal cancer with RAS and BRAF wild-type...
The phase 2 PARERE trial demonstrated an overall response rate and progression-free survival advantage with liquid biopsy-guided anti-EGFR retreatment vs regorafenib for chemorefractory metastatic colorectal cancer with RAS and BRAF wild-type...
The phase 2 PARERE trial...
06/01/2025
Oncology

Recent News

News
Genotype-Guided Therapy Demonstrates High Response and Survival Rates for Patients With R/R DLBCL
09/26/2025
Emily Estrada
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE...
09/26/2025
Oncology
News
PD-1/PD-L1 Inhibitor Monotherapy Demonstrates Accceptable Safety, Limited Efficacy for R/R DLBCL
09/26/2025
Emily Estrada
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large...
09/26/2025
Oncology
News
Polatuzumab-Based Regimens Demonstrate Promising Efficacy for R/R DLBCL Compared to Traditional Salvage Therapies
09/26/2025
Emily Estrada
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional...
09/26/2025
Oncology
FDA Approval
FDA Approves Imlunestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
09/25/2025
Stephanie Holland
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved...
09/25/2025
Oncology
News
Pexidartinib Shows Durable Response Among Patients with Tenosynovial Giant Cell Tumors
09/25/2025
Allison Casey
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained...
09/25/2025
Oncology
News
Clarithromycin-Based Quadruplet Therapy Demonstrates Promising Clinical Responses for Treatment of Relapsed/Refractory Multiple Myeloma
09/24/2025
Emily Estrada
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with...
09/24/2025
Oncology
News
First-Line mFOLFIRINOX, S-IROX Fail to Improve Survival Among Patients With Recurrent or Metastatic Pancreatic Cancer
09/23/2025
Stephanie Holland
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3...
09/23/2025
Oncology
News
Novel Anti-CSF1 Receptor Antibody for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial,...
09/23/2025
Oncology
News
Adverse Events With Pexidartinib for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the...
09/23/2025
Oncology
News
Trifluridine/Tipiracil Plus Bevacizumab Escalation Demonstrates Promise Among Patients With Advanced or Unresectable Metastatic Colorectal Cancer
09/22/2025
Stephanie Holland
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the...
09/22/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use